Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | DRD2 | P14416 | 3/20 | 0.48 |
| ▸ | DRD4 | P21917 | 3/20 | 0.48 |
| ▸ | DRD3 | P35462 | 3/20 | 0.48 |
| ▸ | DRD1 | P21728 | 2/20 | 0.48 |
| ▸ | DRD5 | P21918 | 2/20 | 0.48 |
| ▸ | PDE2A | O00408 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | BACE1 | P56817 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4475739 | 0.90 | CNR2 (0.67) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL4468477 | 0.90 | CNR2 (0.60) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL4474086 | 0.80 | CNR2 (0.82) | CNR2DRD4 | |
| SCHEMBL4481520 | 0.80 | CNR2 (0.53) | CNR2CYP2D6BCHEACHEBACE1 | |
| SCHEMBL4471272 | 0.80 | CNR2 (0.71) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL28226193 | 0.78 | CYP1A2 (0.66) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL4466163 | 0.78 | CNR2 (0.62) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL22794988 | 0.76 | CYP2D6 (0.62) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL22794990 | 0.76 | CYP2D6 (0.62) | CNR2CYP2D6DRD2DRD4DRD3 | |
| SCHEMBL22795508 | 0.76 | CYP2D6 (0.62) | CNR2CYP2D6DRD2DRD4DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-7595397-B2 | Compounds which modulate the CB2 receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-09-29 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070760-A2 | COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191340-A1 | Compounds Which Modulate The CB2 Receptor | CNR1, CNR2, ARRB1 | CNR2 2/4885CYP2D6 930/4885DRD2 211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.